PL3675854T3 - Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3 - Google Patents

Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3

Info

Publication number
PL3675854T3
PL3675854T3 PL18769510.1T PL18769510T PL3675854T3 PL 3675854 T3 PL3675854 T3 PL 3675854T3 PL 18769510 T PL18769510 T PL 18769510T PL 3675854 T3 PL3675854 T3 PL 3675854T3
Authority
PL
Poland
Prior art keywords
glomerulopathy
piperidinyl
treatment
indole derivatives
indole
Prior art date
Application number
PL18769510.1T
Other languages
English (en)
Inventor
Jörg EDER
Richard Alexander Harrison
Boerje Haraldsson
Anna Svenja Schubart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3675854T3 publication Critical patent/PL3675854T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18769510.1T 2017-08-31 2018-08-30 Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3 PL3675854T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17188870 2017-08-31
PCT/IB2018/056618 WO2019043609A1 (en) 2017-08-31 2018-08-30 NEW USES OF PIPERIDINYL-INDOLE DERIVATIVES

Publications (1)

Publication Number Publication Date
PL3675854T3 true PL3675854T3 (pl) 2025-05-19

Family

ID=59745840

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18769510.1T PL3675854T3 (pl) 2017-08-31 2018-08-30 Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3

Country Status (22)

Country Link
US (3) US11723901B2 (pl)
EP (3) EP4647121A2 (pl)
JP (3) JP6754919B1 (pl)
KR (3) KR20240111007A (pl)
CN (5) CN111032042A (pl)
AU (1) AU2018326768B2 (pl)
BR (1) BR112020003737A2 (pl)
CA (1) CA3073346A1 (pl)
CL (1) CL2020000483A1 (pl)
DK (1) DK3675854T3 (pl)
ES (1) ES3022885T3 (pl)
FI (1) FI3675854T3 (pl)
HR (1) HRP20250386T1 (pl)
HU (1) HUE071118T2 (pl)
IL (1) IL272888B2 (pl)
LT (1) LT3675854T (pl)
MX (3) MX2020002185A (pl)
PL (1) PL3675854T3 (pl)
PT (1) PT3675854T (pl)
RS (1) RS66635B1 (pl)
SI (1) SI3675854T1 (pl)
WO (1) WO2019043609A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6754919B1 (ja) 2017-08-31 2020-09-16 ノバルティス アーゲー ピペリジニルインドール誘導体の新規な使用
US20230064254A1 (en) * 2019-12-19 2023-03-02 Taiho Pharmaceutical Co., Ltd. Therapeutic agent containing fused pyrimidine compound as active ingredient
AU2021276912B2 (en) 2020-05-18 2023-12-14 Novartis Ag Crystalline form of LNP023
US20230331710A1 (en) * 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
CN118108700A (zh) * 2020-08-07 2024-05-31 诺华股份有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
MX2023007853A (es) * 2020-12-30 2023-07-07 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
AU2021414253B2 (en) * 2020-12-30 2024-05-16 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Series of piperidine-substituted benzoic acid compounds, and use thereof
IL308166A (en) * 2021-05-07 2024-01-01 Novartis Ag IPTACOPAN for the treatment of atypical hemolytic uremic syndrome
IL310682A (en) * 2021-08-18 2024-04-01 Xizang Haisco Pharmaceutical Co Ltd Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
TW202334121A (zh) * 2021-10-27 2023-09-01 美商翰森生物有限責任公司 哌啶基吲哚衍生物、其製備方法及醫藥用途
PE20242005A1 (es) * 2022-01-24 2024-10-03 Novartis Ag Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos
CN116496249A (zh) * 2022-01-26 2023-07-28 上海美悦生物科技发展有限公司 补体因子b抑制剂的盐型、晶型及其制备方法和应用
CN119343347A (zh) * 2022-06-10 2025-01-21 正大天晴药业集团股份有限公司 双环取代的芳香羧酸酯类化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
CA3260069A1 (en) * 2022-06-30 2025-04-01 Shanghai Hengrui Pharmaceutical Co., Ltd. Pharmaceutically acceptable salt and crystalline form of nitrogen-bridged heterocyclic derivative, and their method of preparation
WO2024051849A1 (en) * 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
CN118026998A (zh) * 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
CN120435467A (zh) * 2022-12-31 2025-08-05 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用
TWI896250B (zh) * 2023-07-26 2025-09-01 大陸商上海美悦生物科技發展有限公司 螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
DK3394089T3 (da) * 2015-12-23 2021-11-01 eleva GmbH Polypeptider til inhibering af komplementaktivering
JP6754919B1 (ja) 2017-08-31 2020-09-16 ノバルティス アーゲー ピペリジニルインドール誘導体の新規な使用
AU2021276912B2 (en) 2020-05-18 2023-12-14 Novartis Ag Crystalline form of LNP023
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors

Also Published As

Publication number Publication date
MX2023010751A (es) 2023-09-20
FI3675854T3 (fi) 2025-04-07
HRP20250386T1 (hr) 2025-05-23
KR20200047540A (ko) 2020-05-07
JP2021181471A (ja) 2021-11-25
JP6929425B2 (ja) 2021-09-01
EP4393545A3 (en) 2024-09-25
JP2020193222A (ja) 2020-12-03
WO2019043609A1 (en) 2019-03-07
CA3073346A1 (en) 2019-03-07
DK3675854T3 (da) 2025-04-07
JP2020529466A (ja) 2020-10-08
KR102497487B1 (ko) 2023-02-08
EP4393545A2 (en) 2024-07-03
CL2020000483A1 (es) 2020-09-04
US20250195493A1 (en) 2025-06-19
EP4647121A2 (en) 2025-11-12
IL272888B1 (en) 2023-09-01
HUE071118T2 (hu) 2025-08-28
KR20240111007A (ko) 2024-07-16
CN111032042A (zh) 2020-04-17
CN117338782A (zh) 2024-01-05
EP4393545B1 (en) 2025-10-08
RU2020111788A3 (pl) 2021-12-28
US12285422B2 (en) 2025-04-29
RS66635B1 (sr) 2025-04-30
CN117398384A (zh) 2024-01-16
EP3675854A1 (en) 2020-07-08
US11723901B2 (en) 2023-08-15
EP3675854B1 (en) 2025-01-22
CN117338783A (zh) 2024-01-05
JP6754919B1 (ja) 2020-09-16
US20200338059A1 (en) 2020-10-29
MX2023010750A (es) 2023-09-20
AU2018326768A1 (en) 2020-02-06
RU2020111788A (ru) 2021-09-30
ES3022885T3 (en) 2025-05-29
IL272888A (en) 2020-04-30
SI3675854T1 (sl) 2025-05-30
US20220152011A1 (en) 2022-05-19
LT3675854T (lt) 2025-04-25
JP7297016B2 (ja) 2023-06-23
CN117338781A (zh) 2024-01-05
KR102682887B1 (ko) 2024-07-08
KR20230024432A (ko) 2023-02-20
BR112020003737A2 (pt) 2020-09-01
PT3675854T (pt) 2025-04-04
IL272888B2 (en) 2024-01-01
MX2020002185A (es) 2020-07-14
AU2018326768B2 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
PL3675854T3 (pl) Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3
ZA201803742B (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL276733A (en) Use of Aribolin in cancer treatment
ZA201807810B (en) Adenosine derivatives for use in the treatment of cancer
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
GB201617064D0 (en) Compounds and their therapeutic use
PT3331610T (pt) Agentes para utilização no tratamento de glioma
GB2538923B (en) A therapeutic agent for use in the treatment of infections
IL246855A0 (en) Materials for use in the treatment of retinitis
PL3675879T3 (pl) Cerebrolizyna do zastosowania w leczeniu cadasil
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL269121A (en) Usl-311 for use in the treatment of cancer
PT3049085T (pt) Inibidores de sgk1 no tratamento da síndrome do qt longo
LT3548006T (lt) Kompozicija, skirta žarnyno pakitimams gydyti
PL3341481T3 (pl) Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne
PT3370727T (pt) Derivados da pregnenolona substituídos em c3 não bioconvertíveis para utilização no tratamento de distúrbios de toxicodependência
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases